Neurocrine Biosciences Outlines 2026 Execution, 2027 Data Milestones

Biotech firm expects Ingrezza revenue of $2.7B-$2.8B in 2026, with pricing pressure from Inflation Reduction Act

Mar. 21, 2026 at 4:03am

Got story updates? Submit your updates here. ›

Neurocrine Biosciences executives outlined plans for 2026 as a year focused on execution, ahead of what they described as a 'data-rich' 2027 with multiple mid- and late-stage clinical program readouts. The company expects its lead drug Ingrezza to generate $2.7 billion to $2.8 billion in revenue in 2026, with pricing pressure from the Inflation Reduction Act starting in 2027. Neurocrine also highlighted progress with its newer drug CRENESSITY and provided updates on its pipeline of neuropsychiatric and endocrine disorder treatments.

Why it matters

Neurocrine's plans for 2026 and 2027 provide insight into the company's strategy to maintain growth momentum for its marketed products while advancing its pipeline. The pricing dynamics around Ingrezza and the impact of the Inflation Reduction Act are closely watched by investors, as is the company's ability to diversify revenue beyond its lead drug.

The details

Neurocrine expects 2026 to be a year of execution, with a focus on driving performance and delivering on phase 2 and phase 3 data readouts in 2027. The company generated just over $2.8 billion in revenue in 2025, with Ingrezza accounting for $2.51 billion of that. Ingrezza revenue is expected to reach $2.7 billion to $2.8 billion in 2026, though the company anticipates a 4-5% year-over-year price decline due to expanded access and contractual dynamics. Neurocrine also plans to leverage improved access and expand its sales force to reach new prescribers. For its newer drug CRENESSITY, the company reached about 10% of the congenital adrenal hyperplasia market in its first year of commercialization in 2025, generating $300 million in revenue. Neurocrine highlighted an 'industry-leading neuropsychiatry portfolio' with several phase 2 and phase 3 readouts expected in 2027, including for osavampator and direclidine.

  • Neurocrine generated $2.8 billion in revenue in 2025.
  • Ingrezza revenue is expected to reach $2.7 billion to $2.8 billion in 2026.
  • Neurocrine plans to expand its sales force in Q2 2026.
  • Teva's Medicare maximum fair price for Austedo is expected to be implemented in 2027-2028.
  • Neurocrine's Medicare maximum fair price for Ingrezza is expected to be implemented in 2029.

The players

Kyle Gano

CEO of Neurocrine Biosciences.

Todd Tushla

Head of investor relations at Neurocrine Biosciences.

Ingrezza

Neurocrine's lead marketed product, indicated for the treatment of tardive dyskinesia.

CRENESSITY

Neurocrine's drug for the treatment of congenital adrenal hyperplasia, which generated $300 million in revenue in its first year of commercialization in 2025.

Austedo

A competing drug to Ingrezza, made by Teva Pharmaceutical, which will be subject to a Medicare maximum fair price starting in 2027-2028.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.